Advertisement

Leptin

Regulation and Clinical Applications

  • Sam Dagogo-Jack, MD

Table of contents

  1. Front Matter
    Pages i-xxiii
  2. Julie Dam, Ralf Jockers, Michèle Guerre-Millo, Karine Clément
    Pages 15-24
  3. Heike Münzberg, Steven B. Heymsfield
    Pages 67-78
  4. Rachel C. Morgan, Robert V. Considine
    Pages 79-88
  5. Faidon Magkos, Elisa Fabbrini, Samuel Klein
    Pages 89-101
  6. Stephen N. Davis, Elizabeth M. Lamos, Hillary Loper, Lisa M. Younk
    Pages 103-115
  7. Richa Pandey, Anubha Mutneja, Daniel W. Coyne, Sam Dagogo-Jack
    Pages 117-129
  8. Giuseppe Matarese, Claudio Procaccini, Valentina Pucino, Christos Mantzoros
    Pages 131-143
  9. Patricia Ducy, Stavroula Kousteni
    Pages 145-161
  10. Olorunseun O. Ogunwobi
    Pages 163-173
  11. Alexandre A. da Silva, Jussara M. do Carmo, Zhen Wang, John E. Hall
    Pages 175-188
  12. Sam Dagogo-Jack
    Pages 189-201
  13. Gilberto Paz-Filho, Julio Licinio
    Pages 203-214
  14. Steven B. Heymsfield, Heike Münzberg
    Pages 215-224
  15. Sharon H. Chou, Christos Mantzoros
    Pages 237-254
  16. Timo D. Müller, Christoffer Clemmensen, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp
    Pages 267-279
  17. Back Matter
    Pages 281-287

About this book

Introduction

Twenty years after its discovery, recombinant human leptin has been approved by the Food and Drug Administration for the treatment of patients with lipodystrophy. Beginning with a synthesis of the vast body of work on its discovery, dissection of mechanisms, and effects in experimental models , the focus of this book shifts to a consideration of the regulation and role of leptin in humans. The emphasis on human-level data is a unique feature of this book. The results of numerous studies indicate that leptin is indeed a regulated human hormone.

Leptin provides a detailed account of the myriad physiological, hormonal, metabolic, immunological, mitogenic and inflammatory modulators and targets of leptin in a single volume. Next follows a comprehensive presentation of the therapeutic trials of recombinant leptin in patients with congenital leptin deficiency, lipodystrophy, hypothalamic amenorrhea, and other emerging areas, including leptin supplementation in leptin-replete subjects, leptin substitution for insulin in diabetic models, and novel combination regimens of leptin and other biogenic peptides. Unanswered questions and future directions in leptin research are highlighted in the Foreword by Dr. Jeffrey Friedman and throughout the volume. Identifying such questions helps direct research that could deepen understanding of the complex regulation of leptin under physiological and pathological conditions, a critical prerequisite to its rational deployment in the treatment of human disorders.

Keywords

Dysleptinemia ELISA Glucocorticoids Homeostasis Hormonal regulation Hypertension Hypothalamus Leptin Leptin therapy Lipodystrophy Metabolic disorder Metreleptin Obesity

Editors and affiliations

  • Sam Dagogo-Jack, MD
    • 1
  1. 1.Division of Endocrinology, Diabetes and MetabolismUniversity of Tennessee Health Science CenterMemphisUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-09915-6
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-09914-9
  • Online ISBN 978-3-319-09915-6
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology